{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:19:39Z","timestamp":1787761179722,"version":"build-2784847793"},"reference-count":25,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 CA193145"],"award-info":[{"award-number":["T32 CA193145"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.modpat.2026.101024","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:40:16Z","timestamp":1781541616000},"page":"101024","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Stratification by Ki-67 Labeling Index Increases Specificity of p16INK4a Expression as a Surrogate Marker for CDKN2A Inactivation in Meningioma"],"prefix":"10.1016","volume":"39","author":[{"given":"Kevin Y.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanish","family":"Mirchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles G.","family":"Eberhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Raleigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8347-9592","authenticated-orcid":false,"given":"Calixto-Hope G.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 4","key":"10.1016\/j.modpat.2026.101024_bib1","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noaf194","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2018-2022","volume":"27","author":"Price","year":"2025","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101024_bib2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00401-020-02188-w","article-title":"CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas","volume":"140","author":"Sievers","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"34","key":"10.1016\/j.modpat.2026.101024_bib3","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.21.00784","article-title":"Integrated molecular-morphologic meningioma classification: a multicenter retrospective analysis, retrospectively and prospectively validated","volume":"39","author":"Maas","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101024_bib4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s40478-023-01690-y","article-title":"CDKN2A\/B deletions are strongly associated with meningioma progression: a meta-analysis of individual patient data","volume":"11","author":"Wach","year":"2023","journal-title":"Acta Neuropathol Commun"},{"issue":"8","key":"10.1016\/j.modpat.2026.101024_bib5","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101024_bib6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/neuonc\/noae170","article-title":"cIMPACT-NOW update 8: clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas","volume":"27","author":"Sahm","year":"2025","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2026.101024_bib7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/neup.12014","article-title":"CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry","volume":"33","author":"Purkait","year":"2013","journal-title":"Neuropathology"},{"issue":"1","key":"10.1016\/j.modpat.2026.101024_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40478-023-01573-2","article-title":"P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas","volume":"11","author":"Vij","year":"2023","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"10.1016\/j.modpat.2026.101024_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/PAS.0000000000002148","article-title":"p16 Immunohistochemistry as a screening tool for homozygous CDKN2A deletions in CNS tumors","volume":"48","author":"Zschernack","year":"2024","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2026.101024_bib10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00401-023-02544-6","article-title":"Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas","volume":"145","author":"Tang","year":"2023","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101024_bib11","article-title":"Molecular prognostication in grade 3 meningiomas and p16\/MTAP immunohistochemistry for predicting CDKN2A\/B status","volume":"6","author":"Tosefsky","year":"2024","journal-title":"Neurooncol Adv"},{"issue":"19","key":"10.1016\/j.modpat.2026.101024_bib12","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.3390\/cancers16193299","article-title":"MTAP and p16 IHC as markers for CDKN2A\/B loss in meningiomas","volume":"16","author":"Ozkizilkaya","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.modpat.2026.101024_bib13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00401-023-02571-3","article-title":"Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas","volume":"146","author":"Wang","year":"2023","journal-title":"Acta Neuropathol"},{"issue":"11","key":"10.1016\/j.modpat.2026.101024_bib14","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2262::AID-CNCR23>3.0.CO;2-R","article-title":"The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas","volume":"82","author":"Perry","year":"1998","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.modpat.2026.101024_bib15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1440-1789.2007.00750.x","article-title":"Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma","volume":"27","author":"Bruna","year":"2007","journal-title":"Neuropathology"},{"issue":"2","key":"10.1016\/j.modpat.2026.101024_bib16","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s11060-025-05057-2","article-title":"Prognostic value of MIB-1 index in meningioma: a retrospective cohort study to establish an optimal cutoff for recurrence and survival","volume":"174","author":"Shukla","year":"2025","journal-title":"J Neurooncol"},{"issue":"5","key":"10.1016\/j.modpat.2026.101024_bib17","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3171\/2025.4.JNS25438","article-title":"Ki-67 in meningioma: distribution and implications","volume":"143","author":"Guo","year":"2025","journal-title":"J Neurosurg"},{"issue":"11","key":"10.1016\/j.modpat.2026.101024_bib18","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/jnen\/nlaf043","article-title":"Adequate capture of spatial heterogeneity of Ki-67 proliferative index in meningiomas requires multiple tissue sections","volume":"84","author":"Ugwuowo","year":"2025","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.modpat.2026.101024_bib19","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nm0795-686","article-title":"5\u2032 CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16\/CDKN2\/MTS1 in human cancers","volume":"1","author":"Merlo","year":"1995","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.modpat.2026.101024_bib20","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","article-title":"Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities","volume":"54","author":"Choudhury","year":"2022","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.modpat.2026.101024_bib21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s11060-025-05029-6","article-title":"Pitfalls in the evaluation of CDKN2A copy number status in meningioma","volume":"173","author":"Zschernack","year":"2025","journal-title":"J Neurooncol"},{"issue":"7","key":"10.1016\/j.modpat.2026.101024_bib22","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/jnen\/nlaf033","article-title":"MTAP immunohistochemistry as a surrogate marker of CDKN2A loss in brain tumors: a meta-analysis and literature review","volume":"84","author":"Dono","year":"2025","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101024_bib23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/jnen\/nlaf131","article-title":"Analysis of anatomical location, mitoses, and Ki-67 in 2608 meningiomas","volume":"85","author":"Broechner","year":"2026","journal-title":"J Neuropathol Exp Neurol"},{"issue":"7","key":"10.1016\/j.modpat.2026.101024_bib24","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/jnen\/nlae035","article-title":"Availability and utilization of molecular testing for primary central nervous system tumors among US hospitals","volume":"83","author":"Parker","year":"2024","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"10.1016\/j.modpat.2026.101024_bib25","first-page":"464","article-title":"Evaluation of prognostic biomarkers in meningiomas and their clinical implications in settings with limited resources","volume":"11","author":"Singh","year":"2024","journal-title":"Neurooncol Pract"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226000670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226000670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:25:35Z","timestamp":1787757935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395226000670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0893395226000670"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101024","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stratification by Ki-67 Labeling Index Increases Specificity of p16INK4a Expression as a Surrogate Marker for CDKN2A Inactivation in Meningioma","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101024"}}